Re: Farmas USA
OVAS
Excitement around OvaScience's recent pregnancy data is "far from universal," and one reproductive biologist said he is "highly troubled" that the company has already moved to human pregnancies, Science Magazine reports. No published animal studies with a control group have been done to test whether OvaScience's approach can improve fertility let alone whether it is safe for offspring, the magazine quotes John Eppig, a reproductive biologist at Jackson Laboratory in Bar Harbor, Maine, as saying. Shares of OvaScience are down 5%, or $2.08, to $36.10 in morning trading
«Después de nada, o después de todo/ supe que todo no era más que nada.»